How to use Tebentafusp-tebn

Tebentafusp-tebn is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Tebentafusp-tebn is available by prescription only and should be used in patients with cancer medications and for the treatment of cytokine release syndrome (CRS). , A potentially life-threatening illness that can cause fever, vomiting, shortness of breath, headache, and hypotension) Use under the supervision of an experienced physician that may occur after treatment with tebenforx , Should be done in an environment where CRS can be managed.

Tebenforx injection is a sterile, preservative-free, clear, colorless or yellowish solution in single-dose vials for intravenous administration by infusion. The recommended dosage is 20 mcg on day 1, 30 mcg on day 8, 68 mcg on day 15, and 68 mcg once weekly thereafter until unacceptable toxicity or disease progression occurs. Dose reduction of tebenforx is not recommended.

Inject the first three doses of tebenforx solution by intravenous infusion over 15-20 minutes in an appropriate medical setting, monitor the patient during the infusion and for at least 16 hours after completion;If the patient does not develop Grade 2 or worse hypotension (requiring medical intervention) during or after the third infusion, administer subsequent doses in an appropriate outpatient care setting and monitor the patient for at least 30 minutes after each infusion.

The original drug of Tibenforsi is not currently on the market in China, nor has it been included in medical insurance. After Tebenforx is approved for marketing, there may be less price and other related information. For more drug information and specific prices, please consult a medical consultant.